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Abstract
Background: Salivary duct carcinoma, an aggressive subtype of salivary gland can-
cer, is mostly androgen receptor-positive. Only limited data are available on androgen
deprivation therapy (ADT).
Methods: Patients with advanced androgen receptor-positive salivary duct carcinoma
treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, par-
tial response [PR] and stable disease, progression-free survival [PFS] and overall
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survival [OS]). The OS was compared with patients with advanced salivary duct car-
cinoma who received best supportive care.
Results: Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients
had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of
50%. The median PFS for the ADT-treated patients was 4 months and the median
duration of clinical benefit was 11 months. The median OS was 17 months versus 5
months in 43 patients receiving best supportive care (P5 .02).
Conclusion: We recommend ADT in advanced androgen receptor-positive salivary
duct carcinoma given its response and clinical benefit.VC 2017 Wiley Periodicals, Inc.
Head Neck 00: 000–000, 2017
KEYWORD S
androgen deprivation therapy, androgen receptors, antineoplastic agents, hormonal, salivary duct carcinoma,
salivary gland neoplasms
1 | INTRODUCTION
Salivary gland cancers comprise a heterogeneous group of
carcinomas. Salivary duct carcinoma is a very aggressive
subtype of salivary gland cancer with a high risk of distant
metastatic disease. The median overall survival (OS) is
approximately 3 years after primary diagnosis.1–3
In case of distant metastatic disease, no standard treatment
options are available and most of the treatments described in
literature are based on small case series or case reports.
Most salivary duct carcinomas express the androgen
receptor4; the percentage of androgen receptor positivity
varies between 67% and 89%.5–7 Based on this androgen
receptor expression, patients have been treated with androgen
deprivation therapy (ADT), such as bicalutamide, an andro-
gen receptor antagonist with a nonsteroidal structure, similar
to the treatment with ADT for patients with prostate cancer.
Due to the rarity of the disease, a clinical study has never
been performed. In 2011, we reported on 10 patients with
salivary duct carcinoma treated with ADT in a single center
(Radboud University Medical Center), with a clinical benefit
rate of approximately 50% and a median progression-free
survival (PFS) of 12 months in patients with clinical benefit.8
The purposes of this retrospective study are to determine the
efficacy of ADT in a nationwide group of patients with
incurable locally advanced or metastatic androgen receptor-
positive salivary duct carcinoma in terms of response, dura-
tion of response, and median OS. In addition, we aim to
describe the outcome of a group of patients with incurable
locally advanced or metastatic salivary duct carcinoma who
received best supportive care during the same period.
2 | PATIENTS AND METHODS
This study was performed in accordance with institutional ethi-
cal guidelines. In a retrospective search by the Nationwide
Network and Registry of Histopathology and Cytopathology
(PALGA) in The Netherlands, we collected all patients diag-
nosed with salivary duct carcinoma in the time period 1990-
2014.9 An experienced pathologist (U.F.) reviewed all pathol-
ogy slides for central confirmation of the diagnosis. This
enabled us to collect data of 177 patients with salivary duct
carcinoma. In The Netherlands, treatment of patients with head
and neck cancer is centralized in 8 head and neck cancer cen-
ters and 6 collaborating major hospitals. Clinical data of all
these patients, including age, sex, primary tumor site, present-
ing symptoms, pathological report (all reviewed), pathological
TNM classification, expression of androgen receptor, develop-
ment of local or locoregional recurrence, or distant metastases,
treatment, such as surgery, radiotherapy, or systemic treatment,
response evaluation in case of systemic treatment, PFS, and
OS, were obtained by reviewing medical records with permis-
sion of the treating physicians. By Dutch law, a review by a
medical ethical committee was not needed due to the retrospec-
tive nature of these observations. Of all 177 patients, only the
86 patients with distant metastatic (n5 84) or incurable locally
advanced salivary duct carcinoma (n5 2) were analyzed in fur-
ther detail. Patients treated with ADT as first-line palliative
treatment were included for analysis about efficacy. Patients
who received any other systemic treatment before ADT were
excluded (chemotherapy, targeted therapy, or adjuvant sys-
temic therapy before ADT). Ten patients of the current series
were already described in an earlier report.8
2.1 | Androgen receptor testing
For all 177 patients with salivary duct carcinoma, efforts
were made to evaluate the androgen receptor. In 140 patients,
the androgen receptor was determined using the androgen
receptor polyclonal antibody of Santa Cruz, dilution 1:200,
pretreatment with citrate (pH 6.0) for 10 minutes in a PT
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module. Immunostaining was carried out with the Powervi-
sion method by Immunologic. The androgen receptor was
scored positive or negative based on diffuse nuclear staining,
as described in the World Health Organization classification
of salivary duct carcinoma.10 For the remaining patients, no
tumor material was available for additional androgen recep-
tor staining. Therefore, the results of androgen receptor deter-
mined during routine clinical care procedures were used.
2.2 | Treatment protocol
Patients who received ADT were treated with 150mg bicalu-
tamide once daily (q.d.) or a combination of a luteinizing
hormone-releasing hormone (LHRH) analog (ie, goserelin
3.6mg subcutaneously every 4 weeks, with 50mg bicaluta-
mide q.d.).
2.3 | Response evaluation
Patients were evaluated approximately every 3 months.
Tumor evaluation was measured using Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1.11 Clinical
benefit was defined as: complete response (CR), partial
response (PR), or stable disease. The PFS was defined as the
time between the start of ADT until the documented date of
progressive disease (PD) or death, whatever came first. The
OS was counted from the date of confirmation of distant
metastasis until the date of death of any cause. Patients alive
at last follow-up were included in the analysis as censored.
Clinical outcomes of ADT-treated patients were com-
pared with clinical outcomes for patients with distant metas-
tasis or incurable locally advanced disease who received best
supportive care.
2.4 | Statistical analysis
The OS was estimated by the Kaplan-Meier survival curves.
The log-rank test was used to compare OS between different
groups of patients. A P value of< .05 was considered
significant.
To study the association between treatment and survival,
an association Cox regression model was fitted to the data.
First, the regression model with only treatment as the inde-
pendent variable was estimated. The hazard ratio in this
model represents the association that is uncorrected for possi-
ble confounders (age, sex, androgen receptor status, primarily
metastasized disease, and organ involvement). Next, the
model was adjusted for possible confounders by a forward
selection procedure. In every step, it was checked whether
one of the possible confounders needed to be added to the
model as an independent variable additional to the variables
already included in the model. By including it into the model,
the variable that causes the biggest change in the association
between treatment and survival (estimate of the regression
coefficient) but at least 10% and had a P value of, at the
most, 10% (Wald-test), was selected for inclusion to the
model. This step was repeated until no variables could be
included to the model. Analyses were performed using SPSS
version 22.0.
3 | RESULTS
3.1 | Patient selection
A total of 177 patients with salivary duct carcinoma were
retrieved from the nationwide search. Eighty-six patients had
incurable locally advanced (n5 2) or metastatic (n5 84) sali-
vary duct carcinoma, of which 38 were treated with ADT. Of
these 38 patients, 3 patients were excluded: 2 patients because
they received chemotherapy as first-line treatment before
ADT, and another patient because of prior adjuvant ADT.
Forty-four patients received best supportive care, of which 1
patient was excluded because this patient received adjuvant
ADT, which led to a total of 43 patients who received best
supportive care only. The other 4 patients received chemo-
therapy and/or targeted therapy only and were not included in
the analysis. Figure 1 shows the flow chart of these patients.
3.2 | Patient characteristics and treatment
The baseline characteristics of the 35 patients receiving first-line
ADT and the 43 patients receiving best supportive care are dis-
played in Table 1. Patients were median 64 and 68 years of
age, and 86% and 81% of the patients were men, respectively.
The percentage of the sites of distant metastases and the number
of sites of distant metastases per patient are shown in Table 1.
Androgen receptor status was determined using the poly-
clonal androgen receptor antibody from Santa Cruz in 17 of
35 ADT-treated patients and 33 of 43 best supportive care-
treated patients. For the remaining patients, no tumor mate-
rial was available for additional androgen receptor staining.
Therefore, the results of androgen receptor as determined
during routine clinical care were used. In 6 best supportive
care-treated patients, the androgen receptor expression was
not determined and, therefore, unknown.
Of the ADT-treated patients, 28 patients (80%) received
single-agent bicalutamide, whereas 7 patients (20%) received
an LHRH analog in combination with low-dose bicalutamide.
Although ADT was usually well tolerated, 1 patient
switched to another form of ADT and 2 male patients (6%)
stopped because of presumed toxicity (ie, fatigue and loss of
appetite).
3.3 | Response to androgen deprivation
therapy and survival
Of the 35 ADT-treated patients, 1 patient requested to dis-
continue treatment before the first evaluation and was left
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out of the response evaluations. Six of 34 evaluable
patients (18%) had a PR, 11 (32%) had stable disease, and
17 (50%) had PD (Table 2). All patients with a PR were
treated with bicalutamide monotherapy. Figure 2 shows
the CT imaging at baseline and after 15 months of ADT
in a patient with PR. In total, 50% had clinical benefit
and stayed on treatment for a median duration of 11
months (95% confidence interval [CI] 6-15 months).
Median PFS for all ADT-treated patients was 4 months
(95% CI 3-5 months; Table 2). At the time of analysis, 6
patients were still on first-line ADT.
The median follow-up time was 10 months (range 1-64
months). The median OS for ADT-treated patients was 17
months (95% CI 10-24 months). The median OS for the
ADT-treated patients with clinical benefit was 29 months
(95% CI 8-51 months) and for patients with PD this was 8
months (95% CI 5-10 months; Table 2). Two of 5 female
patients had a PR on ADT. Possibly because the numbers are
small, we did not observe significant differences in OS or
PFS between male and female patients treated with ADT,
nor did we observe a significant difference between patients
treated with single-agent bicalutamide or LHRH analogs
with bicalutamide.
The median OS for patients treated with best supportive
care was 5 months (95% CI 1-9 months; Table 2). The asso-
ciation between treatment and survival was investigated by
means of estimating a Cox regression model. No confound-
ers were found. The estimated survival curve for ADT-
treated patients in a Cox regression model is shown in Figure
3. The ADT-treated patients had a significantly better OS
than best supportive care patients in this Cox regression
model (P5 .024; hazard ratio 0.53; 95% CI 0.30-0.92).
3.4 | Consecutive systemic treatments
After PD on ADT as first-line treatment, 11 patients received
second-line ADT. Depending on the agents the patients
received as first line, patients were treated with an LHRH ana-
log, either as monotherapy, or combined with bicalutamide
and/or a 5-alfa-reductase-inhibitor. Of the 10 patients treated
FIGURE 1 Flow chart of patients with salivary duct carcinoma (SDC; n5 177) and patients with incurable locally advanced or metastatic salivary
duct carcinoma (n5 86). Patients treated with first-line androgen deprivation therapy (ADT) and patients receiving best supportive care (BSC) are shown.
Text boxes in cursive represent excluded patients
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with first-line bicalutamide monotherapy, 2 patients were con-
secutively treated with an LHRH analog, 7 patients with an
LHRH analog in combination with low-dose bicalutamide
(50mg), and 1 patient with a combination of an LHRH analog,
bicalutamide, and 5-alfa-reductase-inhibitor. One patient treated
with an LHRH analog in combination with low-dose bicaluta-
mide in first-line, was treated in second-line with an LHRH
analog.
Six patients had stable disease for a median of 9 months
(95% CI 6-12 months), 4 patients had PD, and 1 patient did
not have the first evaluation yet. The 6 patients with stable
disease on second-line ADT previously had stable disease (4
patients) or PD (2 patients) on first-line ADT. One patient
received third-line ADT and had stable disease for another 7
months, after also having stable disease, on first-line and
second-line ADT.
Ten patients received chemotherapy as second-line or
third-line treatment after first-line ADT; 2 of those patients
received anti-human epidermal growth factor receptor 2
(HER2) therapy in combination with docetaxel; 1 patient
was treated only with trastuzumab, and the other patient was
treated with a combination of trastuzumab and pertuzumab.
Five patients had a PR, 3 patients had stable disease and 2
patients had PD.
4 | DISCUSSION
Salivary duct carcinoma is a rare and aggressive subtype of
salivary gland cancer. Results on ADT in androgen receptor-
positive incurable locally advanced or metastatic salivary
duct carcinomas are scarce. We aimed to collect data of
patients with salivary duct carcinoma over a period of 25
years in The Netherlands. In this way, we were able to
describe the largest retrospective series of patients with sali-
vary duct carcinoma treated with ADT so far and describe a
TABLE 1 Baseline characteristics of patients with incurable
locally advanced or metastatic salivary duct carcinomas
ADT No. of
patients5 35
BSC No. of
patients5 43
Median age, years, range 64 (38-83) 68 (42-84)
Sex, no. of patients (%)
Male 30 (86) 35 (81)
Female 5 (14) 8 (19)
Androgen receptor
expression,
no. of patients (%)
Positive 35 (100) 35 (81)
Negative 0 2 (5)
Not performed 0 6 (17)
Distant metastasis, no. of
patients (%)
Presenting with distant
metastases
10 (29) 1 (2)
Sequential presentation of
distant metastases
23 (66) 42 (98)
Median time between
diagnosis and
metastases, months (range)
15 (1-69) 14 (1-46)
Sites of distant metastasis,
no. of patients (%)
Lungs 20 (57) 19 (44)
Bones 19 (54) 16 (63)
Lymph nodes 22 (63) 8 (19)
Liver 7 (20) 12 (28)
Brain 3 (9) 8 (19)
Other 5 (14) 5 (12)
No. of involved organs per
patient, no. of patients (%)
0 involved organs 2 (6) 0 (0)
1 involved organ 12 (34) 26 (61)
2 involved organs 6 (17) 11 (26)
3 involved organs 10 (29) 4 (9)
4 involved organs 3 (9) 2 (5)
5 involved organs 2 (6) 0 (0)
Abbreviation: ADT, androgen deprivation therapy; BSC, best supportive care
Patients receiving ADT and best supportive care (BSC) are mentioned
separately.
TABLE 2 Response evaluation, progression-free survival, and
overall survival of androgen deprivation therapy-treated patients
ADT No. of
patients5 35a
BSC No. of
patients5 43
Response evaluation, no.
of patients (%)
PR 6 (18)
Stable disease 11 (32)
PD 17 (50)
Not evaluable 1
Median PFS in months
[95% CI]
4 [3-5]
Median PFS in patients
with PR or stable
disease in months
[95% CI]
11 [6-15]
Median OS in months
[95% CI]
17 [10-24] 5 [1-9]
Abbreviations: ADT, androgen deprivation therapy; BSC, best supportive care;
CI, confidence interval; OS, overall survival; PD, progressive disease; PFS,
progression-free survival; PR, partial response.
The OS for best supportive care patients is also shown.
aThere were 34 evaluable patients.
BOON ET AL. | 609
separate group of patients who received best supportive care
during the same time period. In 35 patients treated with first-
line ADT for salivary duct carcinoma, 18% had PR and 32%
had stable disease, resulting in a clinical benefit rate of 50%
with a median treatment duration of 11 months for patients
with clinical benefit. The median PFS and OS of the ADT-
treated patients were 4 months and 17 months, respectively.
The OS of ADT-treated patients was significantly better than
of best supportive care patients. However, as not all patients
responded to ADT, future research should focus on bio-
markers that predict the response of patients to ADT and
mechanisms of intrinsic and acquired resistance to ADT.12
One may assume that female patients could have less benefit
from ADT due to the lower physiological presence of andro-
gen, and, thus, less stimulation of androgen receptor-positive
tumor cells. However, 2 of 5 female patients had sustained
PR and no differences in OS and PFS for male and female
patients were found.
The incidence of adverse events of ADT-treated patients
seemed to be low, although this may be due to underreport-
ing in this retrospective case series. On the other hand, ADT
is a commonly used therapy for patients with prostate cancer,
with a well-known low toxicity profile.13
Obviously, this study has some limitations. The first one
is its retrospective design, which is largely due to the rarity
of the disease. Performing studies in such rare cancer types
is notoriously difficult and, with a central pathological
review, we have done the best attempt as possible to collect
data of a homogeneous group of patients with salivary duct
carcinoma. Second, we compared OS in ADT-treated
patients with best supportive care patients, which could sug-
gest that bias played a role. Unfortunately, we could not
retrieve the World Health Organization performance score of
patients included in this analysis to investigate this issue.
However, we did perform a Cox regression analysis on OS
to adjust for possible confounders, measured at diagnosis of
incurable locally advanced or metastatic disease. Age, sex,
androgen receptor status, metastasized disease at diagnosis,
and organ involvement were evaluated as possible confound-
ers, but no confounders were found. Additionally, the major-
ity of patients who received ADT were treated in 1 hospital
(74%), because part of the hospitals may not have been
familiar with ADT in patients with androgen receptor-
positive salivary duct carcinoma, which pleads against selec-
tion bias.
Our objective response rate and clinical benefit rate on
ADT in patients with androgen receptor-positive locally
advanced or metastatic salivary duct carcinoma might be
slightly lower than case series described in literature
FIGURE 2 One of the 6 patients with a partial response on androgen deprivation therapy (ADT). Baseline CT imaging of mediastinal lymph nodes
(left) and after 15months of ADT (right). The patient was treated with bicalutamide alone [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 Cox regression survival curves for all androgen depriva-
tion therapy (ADT)-treated versus best supportive care (BSC) patients.
The ADT-treated patients had significantly better overall survival com-
pared with patients receiving best supportive care (P5 .024; hazard ratio
0.53; 95% confidence interval 0.30-0.92) [Color figure can be viewed at
wileyonlinelibrary.com]
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(Table 3).8,14,15 Locati et al14 reported on 17 patients with
androgen receptor-positive salivary gland cancer (ie, salivary
duct carcinoma and also other adenocarcinomas) treated with
ADT and found an overall response rate of 65%. Of the 8
patients with salivary duct carcinoma, 2 patients had CR, 2
patients had PR, and 3 patients had stable disease. Further-
more, Yajima et al15 reported on 8 patients with salivary
duct carcinoma, with 2 patients with PR and 3 patients with
stable disease.
In addition to ADT, other therapies may be considered.
In a retrospective series of 18 patients with salivary duct car-
cinoma treated with carboplatin and paclitaxel, they had a
median PFS of 6.5 months and median OS of 34.7 months.16
In case of HER2-positive salivary duct carcinoma, which is
observed in 21%-44% of patients with salivary duct carci-
noma, trastuzumab may be added to chemotherapy.17,18 In
fact, trastuzumab-based treatment regimens have shown
some promising responses. In 2 separate reports, a total of 8
patients were treated with paclitaxel, carboplatin, and trastu-
zumab. Two patients had CR (duration 36 and 52 months)
and 2 patients had PR (duration 20 and 36 months).19,20
Basket studies may offer a promising way to investigate
new treatment options for patients with salivary duct carci-
noma with targetable mutations. Two case reports mentioned
response on temsirolimus and bevacizumab in patients with a
somatic phosphotidylinositol-3-kinase mutation, and on
vemurafenib in a patient with a somatic B-type Raf muta-
tion.21,22 Whole genome sequencing may reveal other target-
able mutations.
Currently, no treatment algorithms exist for patients with
metastatic salivary duct carcinoma. Based on our results and
literature, we suggest as first-line treatment ADT in androgen
receptor-positive salivary duct carcinoma due to efficacy and
tolerability. The choice of bicalutamide monotherapy or
LHRH analog with low-dose bicalutamide depends on
patient characteristics, such as age and sex. Multiple lines of
ADT may be given before considering chemotherapy. In
patients with a more aggressive course of the disease, chemo-
therapy may be considered. In HER2-positive salivary duct
carcinoma, trastuzumab and pertuzumab may be added to
chemotherapy. One of the patients treated with docetaxel,
pertuzumab, and trastuzumab after ADT was discussed in a
separate paper.23 Finally, patients can be analyzed for target-
able mutations and treated accordingly.
For future research, combining chemotherapy with ADT
in androgen receptor-positive salivary duct carcinoma may
be interesting as an analog to recent insights in prostate can-
cer (CHAARTED trial).24 In this randomized trial, first-line
ADT was compared to docetaxel plus ADT and showed a
significant OS benefit for the latter.
A randomized phase II European Organisation for
Research and Treatment of Cancer trial (clinical trial number
NCT01969578) is currently including patients with androgen
receptor-positive recurrent or metastatic salivary gland carci-
nomas. Patients are randomized between chemotherapy
(either cisplatin with doxorubicin or carboplatin with pacli-
taxel) and ADT (triptorelin and bicalutamide). The results of
this trial will probably give more insight in treatment for
androgen receptor-positive salivary gland cancer.
One may wonder, with the aggressive behavior of sali-
vary duct carcinoma, and the shown efficacy of ADT in the
metastatic setting, if adjuvant treatment with ADT is
TABLE 3 Overview of studies on treatment with androgen deprivation therapy for patients with androgen receptor-positive salivary duct
carcinoma
Author No. of patients ADT Results
CR (%) PR (%)
Stable
disease (%) PD (%)
Clinical
benefit, %
Current papera 35b Bicalutamide1 /- LHRH
analogue
0 6 (18) 11 (32) 17 (50) 50
Jaspers et al8 10 Bicalutamide1 /- LHRH
analogue
0 2 (20) 3 (30) 5 (50) 50
Locati et al14 8 Bicalutamide or cyproterone
acetate (1 patient)1LHRH
analogue
2 (25) 2 (25) 3 (38) 1 (13) 87
Yajima et al15 8 LHRH analogue 0 2 (25) 3 (38) 3 (38) 63
Abbreviations: ADT, androgen deprivation therapy; CR, complete response; LHRH, luteinizing hormone-releasing hormone; PD, progressive disease; PR, partial
response.
aTen patients described in the current article were published before.8
bThere were 34 evaluable patients.
Clinical benefit is CR1PR1 stable disease.
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warranted. The benefit of adjuvant ADT will, however, be
difficult to demonstrate.
In conclusion, treatment with ADT in androgen receptor-
positive salivary duct carcinoma can be recommended given
its response, clinical benefit, and median OS benefit as com-
pared with patients treated with best supportive care. Further
research to select patients with androgen receptor-positive
salivary duct carcinoma who are most likely to benefit from
ADT is warranted.
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